Lavleen K Mader (Lavleen Mader)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Prostate Cancer

Structure Activity Relationship

Top Venues

RSC medicinal chemistry

ACS medicinal chemistry letters

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Lavleen K Mader, Jeffrey W Keillor
Fitting of k inact and K I Values from Endpoint Pre-incubation IC 50 Data. ACS medicinal chemistry letters 15 (5) (2024)
Lavleen K Mader, Jeffrey W Keillor
Fitting of k inact and K I Values from Endpoint Pre-incubation IC 50 Data. ACS medicinal chemistry letters 15 (5) (2024)
Martin K Bakht, John J Hayward, Farsheed Shahbazi-Raz, Magdalena Skubal, Ryo Tamura, Keith F Stringer, Daniel Meister, Varadha Balaji Venkadakrishnan, Hui Xue, Adam Pillon, Mathew Stover, Adam Tronchin, Bre-Anne Fifield, Lavleen K Mader, Sheng-Yu Ku, Gi Jeong Cheon, Keon-Wook Kang, Yuzhuo Z Wang, Xuesen Dong, Himisha Beltran, Jan Grimm, Lisa A Porter, John F Trant
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 119 (4) (2022)
Lavleen K Mader, Sarah K I Watt, Harish R Iyer, Linh Nguyen, Harpreet Kaur, Jeffrey W Keillor
The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors. RSC medicinal chemistry 14 (2) (2022)
Lavleen K Mader, Sarah K I Watt, Harish R Iyer, Linh Nguyen, Harpreet Kaur, Jeffrey W Keillor
The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors. RSC medicinal chemistry 14 (2) (2022)